Document is current
Any future updates will be listed below
-
Authors
Benussi, Alberto
Cantoni, Valentina
Rivolta, Jasmine
Archetti, Silvana
Micheli, Anna
Ashton, Nicholas
Zetterberg, Henrik
Blennow, Kaj
Borroni, Barbara
-
Funding
Funding for this research was provided by:
Fondazione Cariplo (2021-1516)
Associazione Italiana Ricerca Alzheimer
Swedish Research Council (2018-02532, 2017-00915)
European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-71320)
Alzheimer's Drug Discovery Foundation (201809-2016862, RDAPB-201809-2016615)
AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C)
Olav Thon Foundation
Erling-Persson Family Foundation
Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (FO2019-0228)
European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (No 860197 (MIRIADE))
European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694)
UK Dementia Research Institute at UCL (UKDRI-1003)
Swedish Alzheimer Foundation (AF-742881)
Hjärnfonden, Sweden (FO2017-0243)
Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (ALFGBG-715986)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
National Institute of Health (NIH), USA (1R01AG068398-01)
Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495)
Italian Ministry of Health (RF-2018-12366665, RF-2018-12366665)
- License Information
-
More Information
Article History
Received: 12 April 2022
Accepted: 22 September 2022
First Online: 13 October 2022
Declarations
:
: Full written informed consent was obtained from all subjects according to the Declaration of Helsinki. The Brescia Ethics Committee approved the study protocol.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant at advisory boards or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. BB has served at scientific boards for Denali, Wave, Alector, and Aviadobio.
